Skip to main content
Clinical Trials/NCT05898243
NCT05898243
Recruiting
Not Applicable

Prospective Descriptive Study of Injuries Associated to Anterior Shoulder Dislocations in Patients Over 40 Years

Corporacion Parc Tauli1 site in 1 country120 target enrollmentJune 1, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Anterior Glenohumeral Dislocations
Sponsor
Corporacion Parc Tauli
Enrollment
120
Locations
1
Primary Endpoint
Characterization of associated lesions
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

The glenohumeral joint has the highest rate of dislocation of the whole body, due to its high mobility and the special characteristics of its anatomy. It is estimated that every year between 1-2% of the population will suffer from glenohumeral dislocation. The vast majority of studies are based on young patients under the age of 40, given that at this age they have the higher incidence and at the same time, they have higher redislocation index. However, the investigators are in front of a more active population with a longer life expectancy. That is why the cases of anterior glenohumeral dislocations are increasing in people older than 40 years. Given that most studies focus on younger patients, the investigators lack knowledge about which injuries are associated with dislocation at this age and whether these influence its clinical evolution.

Registry
clinicaltrials.gov
Start Date
June 1, 2023
End Date
May 31, 2028
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Corporacion Parc Tauli
Responsible Party
Principal Investigator
Principal Investigator

Mònica Salomó Domènech

Doctor

Corporacion Parc Tauli

Eligibility Criteria

Inclusion Criteria

  • More than 40 years old
  • First episode of traumatic anterior gelnohumeral dislocation seen in Rx
  • Acceptance to be checked over 2 years
  • Acceptance to be submitted to TAC, NMR, EMG and Bilateral Ultrasound

Exclusion Criteria

  • Previous fractures in this extremity
  • Previous neurovascular lesions in this extremity
  • Other associated lesions
  • Cognitive alterations or dementia which prevent completing the protocols. Patients with \<14 points in Mini-mental test.

Outcomes

Primary Outcomes

Characterization of associated lesions

Time Frame: At the three months visit including assessment of NMR/EMG/TAC/Bilateral Ultrasound

Secondary Outcomes

  • Constant Functional Test(3, 6, 12 and 24 months)
  • WOSI test(3, 6, 12 and 24 months)
  • SST(3, 6, 12 and 24 months)
  • Redislocations(3, 6, 12 and 24 months)
  • Type of treatment(3, 6, 12 and 24 months)

Study Sites (1)

Loading locations...

Similar Trials